Entrepreneur-eye surgeon continues his family's legacy in the field of ophthalmology, as Eyenovia's new Chairman

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Before founding Eyenovia, Dr. Sean Ianchulev had established himself as a pioneer and innovator in the field of ophthalmology. Inspired by his mother, a former retina surgeon, clinician, and university professor, Dr. Ianchulev would successfully carve a path of his own, pioneering several breakthroughs in the field of ophthalmology while serving as Eyenovia's Chief Executive Officer, its Chief Medical Officer and a member of its Board of Directors.

In early June, Dr. Ianchulev announced he would transition to Chairman of the company's Board of Directors to focus on strategy and on the next horizon of innovations in the ophthalmic field.

At 18, Ianchulev emigrated to the United States from post-communist Bulgaria with only $200 in his pocket. Medicine was viewed as a public service rather than a prestigious career choice in his home country. Spending time around his mother and her patients would serve as the inspiration that would motivate Ianchulev to pursue a career in medicine.

As an innovator and technology developer, he has been at the forefront of medical innovation - inventing and developing medical technologies which have transformed the ophthalmic medical field and are improving vision for hundreds of thousands of patients every year. Dr. Ianchulev is a holder of many issued and pending patents and has high-impact publications in the ophthalmic field, which have been cited by more than 3,000 peer-reviewed publications.

Recognized for his leadership in public health, and innovation in medicine, Dr. Ianchulev has been invited by the United States Congress to speak as an expert during discussions on medical innovation and FDA regulation. He also sits on a number of corporate and advisory boards.

While at Genentech, Dr. Ianchulev headed the ophthalmology clinical group and directed the development and the FDA approval of Lucentis®, one of the most successful biotech innovations in the field of ophthalmology. Dr. Ianchulev is also the inventor of the first ophthalmic intraoperative biometry device (ORA, Alcon) for high precision, infrared laser-guided cataract surgery, which dramatically improved the outcomes of cataract surgery and has been used to treat several million patients to date. Dr. Ianchulev was the patent holder and technology founder of Wavetec Inc., which was acquired by Alcon.

In the glaucoma field, Dr. Ianchulev invented the first virtual perimetry device for the screening and early detection of glaucoma - now transforming remote patient care with the KYS (KeepYourSight) vision care system. He was also at the forefront of developing Micro-Incisional Glaucoma Surgery (MIGS) technology and led the development of the first supraciliary micro-stent while at Transcend Medical - a company acquired by Novartis.

As the founder of Eyenovia, Dr. Ianchulev has spearheaded next generation ophthalmic drug delivery with the first technology to transform the 100-year-old eye care paradigm. By "shrinking" the ink-jet printer technology to a palm-size smart delivery device and using high-precision horizontal micro-dosing for topical eye therapies, Optejet™ by Eyenovia can now deliver pixel size droplets and gently "print" medications on the cornea surface without spillage, waste, overdosing and discomfort.

In addition, Eyenovia's technology may be able to be used to deliver eye therapy to astronauts in space, in a zero gravity environment. Using piezo-print technology, Eyenovia is embarking on new treatments for high impact global diseases affecting hundreds of millions of people including presbyopia and childhood myopia.

In the field of advanced micro-interventional technology for cataract surgery and next generation devices, Dr. Ianchulev is the inventor and co-founder of Iantech, Inc., which includes the development of miLOOP® - acquired by Carl Zeiss Meditec. He is also one of the first pioneers of robotic micro-interventional ophthalmic surgery and was the developer of the first system for robotic glaucoma surgery with the PRECEYES eye surgical robot.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.

Contact Information: Norbert Lowe Vice President, Commercial Operations nlowe@eyenovia.com Buse Kayar buse@newswire.com

Image 1: Dr. Sean Ianchulev Dr. Sean Ianchulev

This content was issued through the press release distribution service at Newswire.com.

The 86-year-old investing legend has spoken. You may want to pay attention.

Stock splits have been all the rage this year as several prominent companies have decided to go down this path to lower their share prices and boost the demand among retail investors at a time when the broader market has been in sell-off mode, but even this move hasn't given them reprieve on the stock market. Palo Alto Networks (NASDAQ: PANW), for instance, announced a three-for-one stock split on Aug. 22. Shares of the cybersecurity specialist shot up following the announcement, but they have lost momentum since thanks to the Federal Reserve's hawkish nature that has been weighing on the stock market this year.

Currently, AT&T sports a high 7.4% dividend yield, which means the company will pay an estimated 7.4% of its stock price to shareholders each year. This number constantly fluctuates because it is calculated using the annual dividend payout divided by the stock price. The yield rises if the dividend goes up and the stock price stays the same.

At 92 and 86 years of age, respectively, Warren Buffett and Carl Icahn are two of the greatest living investors  -- and both are still at it! In fact, these two seniors have been quite active this year, especially around oil giant Occidental Petroleum (NYSE: OXY). On the flip side, Warren Buffett has been buying Occidental shares hand over fist throughout the year, scooping up over 20% of the American oil driller.

(Bloomberg) -- Tesla Inc. shares tumbled about 50% from their all-time high, amid a broader selloff in the US stock market that has hit growth and technology companies especially hard. Most Read from BloombergNATO-China Tension Over Ukraine Flares at Conference in IcelandRolex Prices to Drop Further as Supply Surges: Morgan StanleyDiesel Hits Chaos Mode in Fresh Blow for Global EconomyThe electric vehicle-maker’s shares closed down 7.6% to $204.99 on Friday, taking its market capitalization to $

Both companies have seen their share price fall, but that doesn't mean Apple or Amazon wouldn't be interested at the right number.

It's never a dull time analyzing Tesla's (NASDAQ: TSLA) stock. The innovative electric-car company always seems to have something interesting going on. In this video, we take a beginner-friendly walk-through of Tesla's second-quarter earnings transcript.

These diversified natural-resource giants have solid balance sheets, earnings, and dividends. All that they need is a rebound in commodity prices.

The premium being paid by Kroger (KR) for the company's merger values ACI closer to its 52-week highs and could eventually give the stock another short-term catalyst. With or without the merger, ACI stock may be worth investors' consideration as its growth outlook has become more intriguing.

Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Plug Power Inc. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.

Wall Street in the week ahead will turn to quarterly results from companies like streaming giant Netflix Inc. and electric-vehicle maker Tesla Inc.

The research firm came up with a list of the best companies to own based on ones to which Morningstar analysts assign a wide moat.

A new rally attempt is already struggling. Netflix and Tesla earnings loom. Shockwave is a stock to watch.

The economist warned in 2006 that the U.S. housing bust would cause a financial crisis. Now he has a new economic doomsday prediction, and it isn't pretty.

Investors searching for safe places to store some cash amid high inflation and volatile markets have options. In continuation of Yahoo Finance's series 'What to do in a bear market', we asked the experts where to park money safely, amid high inflation.

The U.S. Treasury Department put an item on its agenda Friday to start talking with primary dealers about the potential for it to buy back some of its older debt to help keep markets functioning smoothly.

This week’s worse-than-expected inflation report led to turmoil in more than one market, but you only read about one of them. What got far less attention was the flurry of excitement that the inflation report caused in the normally-staid I-bond market.

The Nasdaq Composite Index has tumbled more than 35% from its recent peak, putting it in a deep bear market. With their share prices tumbling, they trade at much lower valuations. Because of that, investors could score big gains by taking advantage of the sell-off and holding through the eventual recovery.

The electric vehicle industry is pining for the next generation of lithium batteries that will improve range and charge times. QuantumScape thinks it has a solution.

Investors have become more confident that the company can put the past behind it as demand for air travel recovers.